Chinese PLA General Hospital (CAR-T cell technology) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Chinese PLA General Hospital (CAR-T cell technology) General Information

Description

Biologic cancer therapy asset. The asset consists of Chimeric Antigen Receptor T cell (CAR-T) therapy, its recombinant expression vector CD19, CD20, CD30 and human epidermal growth factor receptor's immuno-oncology patents, and phase I/II clinical data of the therapies and manufacturing knowledge. The CAR-T cell therapy involves engineering cancer patients' own immune cells to recognize and attack their tumors.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Pharmaceuticals
Acquirer
Corporate Office
  • 28 fuxing road
  • Beijing
  • China

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Chinese PLA General Hospital (CAR-T cell technology) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Chinese PLA General Hospital (CAR-T cell technology)‘s full profile, request access.

Request a free trial

Chinese PLA General Hospital (CAR-T cell technology) Patents

Chinese PLA General Hospital (CAR-T cell technology) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240033253-A1 Photocurable hydrogel loaded with vh298-modified exosome and method of preparation and use thereof Pending 29-Jul-2022 0000000000
EP-4267753-A1 Methods and reagents for high-throughput drug screening Pending 22-Dec-2020 0000000000
US-20240044870-A1 Methods and reagents for high-throughput drug screening Pending 22-Dec-2020 00000000000
EP-4260826-A1 Fracture repair device capable of achieving transition from mechanical osteosynthesis (ao) to biological osteosynthesis (bo) Pending 11-Dec-2020 000000000
US-20240041508-A1 Fracture repair device realizing transition from mechanical fixation (association of osteosynthesis, ao) to biological fixation (biological osteosynthesis, bo) Pending 11-Dec-2020 A61B17/808
To view Chinese PLA General Hospital (CAR-T cell technology)’s complete patent history, request access »

Chinese PLA General Hospital (CAR-T cell technology) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Chinese PLA General Hospital (CAR-T cell technology)‘s full profile, request access.

Request a free trial

Chinese PLA General Hospital (CAR-T cell technology) FAQs

  • Where is Chinese PLA General Hospital (CAR-T cell technology) headquartered?

    Chinese PLA General Hospital (CAR-T cell technology) is headquartered in Beijing, China.

  • What industry is Chinese PLA General Hospital (CAR-T cell technology) in?

    Chinese PLA General Hospital (CAR-T cell technology)’s primary industry is Buildings and Property.

  • Is Chinese PLA General Hospital (CAR-T cell technology) a private or public company?

    Chinese PLA General Hospital (CAR-T cell technology) is a Private company.

  • What is the current valuation of Chinese PLA General Hospital (CAR-T cell technology)?

    The current valuation of Chinese PLA General Hospital (CAR-T cell technology) is 00.000.

  • What is Chinese PLA General Hospital (CAR-T cell technology)’s current revenue?

    The current revenue for Chinese PLA General Hospital (CAR-T cell technology) is 000000.

  • Who are Chinese PLA General Hospital (CAR-T cell technology)’s investors?

    Chinese PLA General Hospital has invested in Chinese PLA General Hospital (CAR-T cell technology).

  • When was Chinese PLA General Hospital (CAR-T cell technology) acquired?

    Chinese PLA General Hospital (CAR-T cell technology) was acquired on 09-Feb-2015.

  • Who acquired Chinese PLA General Hospital (CAR-T cell technology)?

    Chinese PLA General Hospital (CAR-T cell technology) was acquired by AbelZeta.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »